Newsroom

Patient Navigation in Immuno-Oncology


(AJMC.org) BEING DIAGNOSED WITH CANCER is often the scariest news a patient will hear in his or her lifetime. In addition to the physical toll of the disease itself, there are numerous other factors associated ...

Cooling Down ICER? Five Questions to Consider


(ACCCBuzz) Jan 25, 2017 – Although the value-based reimbursement train has definitely left the station and is picking up speed, those in the oncology community continue to grapple with the thorny ...

AstraZeneca Delivers New Data on Expanding Portfolio of Cancer Medicines at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting


(AstraZeneca) May 26, 2017 - Investigational data for Lynparza™ (olaparib) tablets in BRCA-mutated metastatic breast cancer to be highlighted in plenary presentation of Phase III OlympiAD trial; key investigational trials show further evidence of Tagrisso® (osimertinib) effect in patients with EGFR T790M mutation-positive non-small cel...

Urothelial Carcinoma Experts Optimistic for Durvalumab/Tremelimumab Combo


(Targeted Oncology) May 23, 2017 - The recent explosion of FDA approvals in the field of urothelial carcinoma, first and foremost, offers patients options for subsequent lines of therapy, says Peter Black, MD. However, it also raises the question of which of these 5 immunotherapy agents physicians should use. ...

U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated Hepatocellular Carcinoma


(BMS) May 24, 2017 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) that seeks to extend the use of Opdivo (nivolumab) to patients with hepatocellular carcinoma (HCC) after prior sorafenib therapy. ...